English

设为首页 | 加入收藏 | 联系我们

首页 >> 研究生教育 >> 导师介绍 >> 博士生导师

陈乃宏

时间:2021/6/19 来源: 阅读:57125次


陈乃宏

 

(一)基本信息及联系方式:

陈乃宏,男,研究员。

联系电话:63165177

联系邮箱:chennh@imm.ac.cn

 

 

 

(二)个人简介

1. 工作经历

1997.04―2000.07  日本 三菱公司 生命科学研究所 博士后

2000.07―2001.09  日本 理化研究所 前沿研究部门 研究员

2002.09―2004.10  日本 北里大学 医学院 客座教授

2001.09至今     中国医学科学院 药物研究所 研究员,博导

2013.05―至今     中国医学科学院神经科学中心副主任

2. 教育背景

1993.03―1997.03   日本国立琦玉大学获博士学位

3. 在研项目

主持国家自然科学基金重点项目1项、面上项目1项;主持国家重大新药创制科技重大专项 1项;主持北京协和医学院高端外国专家引进计划项目1项;参与国家重大新药创制科技重大专项2项。

(四)研究方向

本课题组主要从事神经药理学、神经分子生物学、中药药理学、神经系统疾患及炎症相关疾患的创新药物开发及机理研究。主要研究内容包括:

1、抗神经退行性疾病(PD/AD)创新药物研发及机制分析;

2、抗脑缺血创新药物研发及机制研究;

3、基于CKLF1为靶点的创新药物研发及机制分析;

4、抗抑郁症创新药物研发及机制分析;

5、荧光可视化技术在神经精神系统药物研究中的应用;

6、天然产物及中药创新药物的发现及作用机制研究。

 

(五)科研成果

发表论文

1.     The Therapeutic Role of Cannabinoid Receptors and Its Agonists or Antagonists in Parkinson's Disease. Han QW#, Yuan YH*, Chen NH*. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Jan 10;96:109745.

2.     CZ-7, a New Derivative of Claulansine F, Promotes Remyelination Induced by Cuprizone by Enhancing Myelin Debris Clearance. Wang SS#, Bi HZ, Chu SF, Dong YX, He WB, Tian YJ, Zang YD, Zhang DM, Zhang Z*, Chen NH*. Brain Res Bull. 2020 Apr 11;159:67-78.

3.     Potential Application of Endocannabinoid System Agents in Neuropsychiatric and Neurodegenerative Diseases-Focusing on FAAH/MAGL Inhibitors. Ren SY#, Wang ZZ, Zhang Y, Chen NH*. Acta Pharmacol Sin. 2020 Oct;41(10):1263-1271.

4.     Donepezil Attenuates Vascular Dementia in Rats Through Increasing BDNF Induced by Reducing HDAC6 Nuclear Translocation. Jian WX#, Zhang Z, Zhan JH, Chu SF, Peng Y, Zhao M, Wang Q, Chen NH*. Acta Pharmacol Sin. 2020 May;41(5):588-598.

5.     Anti-inflammatory effects of higenamine (Hig) on LPS-activated mouse microglia (BV2) through NF-κB and Nrf2/HO-1 signaling pathways. Yang SW#, Chu SF, Ai QD, Zhang Z, Gao Y, Lin MY, Liu YJ, Hu YM, Li X, Peng Y, Pan YW, He QH, Chen NH*. Int Immunopharmacol. 2020 Aug;85:106629.

6.     Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells. Shao QH#, Yan WF#, Zhang Z, Ma KL, Peng SY, Cao YL, Yuan YH*, Chen NH*. Neuropharmacology. 2019 Jan;144:388-399.

7.     Ginsenoside Rg1 protects against ischemic/reperfusion-induced neuronal injury through miR-144/Nrf2/ARE pathway. Chu SF#, Zhang Z, Zhou X, He WB, Chen C, Luo P, Liu DD, Ai QD, Gong HF, Wang ZZ, Sun HS, Feng ZP, Chen NH*. Acta Pharmacol Sin. 2019 Jan;40(1):13-25.

8.     IMM-H004 protects against oxygen-glucose deprivation/reperfusion injury to BV2 microglia partly by modulating CKLF1 involved in microglia polarization. Chen C#, Ai QD, Chu SF, Zhang Z, Zhou X, Luo P, Liu YJ, Chen NH*. Int Immunopharmacol. 2019 Feb 20;70:69-79.

9.     RNAi-mediated knockdown of DJ-1 leads to mitochondrial dysfunction via Akt/GSK-3ß and JNK signaling pathways in dopaminergic neuron-like cells. Zhang XL#, Wang ZZ, Shao QH, Zhang Z, Li L, Guo ZY, Sun HM, Zhang Y*, Chen NH*. Brain Res Bull. 2019 Mar;146:228-236.

10.  The effects of glucocorticoids on depressive and anxiety-like behaviors, mineralocorticoid receptor-dependent cell proliferation regulates anxiety-like behaviors. Chen J#, Wang ZZ, Zhang S, Chu SF, Mou Z, Chen NH*. Behav Brain Res. 2019 Apr 19;362:288-298.

11.  The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Wang S#, Yuan YH*, Chen NH*, Wang HB. Int Immunopharmacol. 2019 Feb;67:458-464.

12.  CZ-7, a new derivative of Claulansine F, ameliorates 2VO-induced vascular dementia in rats through a Nrf2-mediated antioxidant responses. Liu DD#, Yuan X#, Chu SF, Chen C, Ren Q, Luo P, Lin MY, Wang SS, Zhu TB, Ai QD, Zang YD, Zhang DM, He X, Huang ZH, Sun HS, Feng ZP, Chen NH*. Acta Pharmacol Sin. 2019 Apr;40(4):425-440.

13.  IMM-H004 Protects against Cerebral Ischemia Injury and Cardiopulmonary Complications via CKLF1 Mediated Inflammation Pathway in Adult and Aged Rats. Ai QD#, Chen C, Chu SF, Luo Y, Zhang Z, Zhang S, Yang PF, Gao Y, Zhang XL, Chen NH*. Int. J. Mol. Sci. 2019, 20, 1661.

14.  A20 as a novel target for the anti-neuroinflammatory effect of chrysin via inhibition of NF-κB signaling pathway. Li ZP#*, Chu SF#, He WB, Zhang Z, Liu JQ, Cui LY, Yan X, Li DF*, Chen NH*. Brain Behav Immun. 2019 Jul; 79:228-235.

15.  CKLF1 Aggravates Focal Cerebral Ischemia Injury at Early Stage Partly by Modulating Microglia/Macrophage Toward M1 Polarization Through CCR4. Chen C#, Chu SF, Ai QD, Zhang Z, Guan FF, Wang SS, Dong YX, Zhu J, Jian WX, Chen NH*. Cell Mol Neurobiol. 2019 Jul;39(5):651-669.

16.  NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. Chen Y#, Zhang QS, Shao QH, Wang S, Yuan YH*, Chen NH*, Wang HB. Acta Pharmacol Sin. 2019 Aug;40(8):991-998.

17.  IMM-H004 therapy for permanent focal ischemic cerebral injury via CKLF1/CCR4-mediated NLRP3 inflammasome activation. Ai QD#, Chen C, Chu SF, Zhang Z, Luo Y, Guan FF, Lin MY, Liu DD, Wang SS, Chen NH*. Transl Res. 2019 Oct;212:36-53.

18.  TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease. Shao QH#, Chen Y, Li FF, Wang S, Zhang XL, Yuan YH*, Chen NH*. Acta Pharmacol Sin. 2019 Dec;40(12):1503-1512.

19.  Chemokines play complex roles in cerebral ischemia. Chen C#, Chu SF, Liu DD, Zhang Z, Kong LL, Zhou X, Chen NH*. Neurochem Int. 2018 Jan;112:146-158.

20.  Gap junction channels as potential targets for the treatment of major depressive disorder. Ren Q#, Wang ZZ, Chu SF, Xia CY, Chen NH*. Psychopharmacology (Berl). 2018 Jan;235(1):1-12. 

21.  RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Zhang Z#, Chu SF#, Wang SS, Jiang YN, Gao Y, Yang PF, Ai QD, Chen NH*. Br J Pharmacol. 2018 Feb;175(4):590-605.

22.  NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. Wen L#, Zhang QS, Heng Y, Chen Y, Wang S, Yuan YH*, Chen NH*. Toxicol Lett. 2018 May 15;288:1-8.

23.  A novel mechanism of depression: role for connexins. Xia CY#, Wang ZZ, Yamakuni T, Chen NH*. Eur Neuropsychopharmacol. 2018 Apr;28(4):483-498.

24.  Anti-neuroinflammatory effects of 20C from Gastrodia elata via regulating autophagy in LPS-activated BV-2 cells through MAPKs and TLR4/Akt/mTOR signaling pathways. Shao QH#, Zhang XL, Chen Y, Zhu CG, Shi JG, Yuan YH*, Chen NH*. Mol Immunol. 2018 Jul;99:115-123.

25.  Prion-like propagation of α-synuclein in the gut-brain axis. Chen Y#Shao QH, Yuan YH*Chen NH*. Brain Res Bull. 2018 Jun;140:341-346.

26.  Glucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats. Lou YX#, Li J, Wang ZZ, Xia CY, Chen NH*. Psychopharmacology (Berl). 2018 Sep;235(9):2529-2540.

27.  Ursodeoxycholic acid protects interstitial Cajal-like cells in the gallbladder from undergoing apoptosis by inhibiting TNF-α expression. Wan JF#, Chu SF, Zhou X, Li YT, He WB, Tan F, Luo P, Ai QD, Wang Q, Chen NH*. Acta Pharmacol Sin. 2018 Sep;39(9):1493-1500.

28.  The extended application of the rat brain in stereotaxic coordinates in rats of various body weight. Yang PF#, Wang ZZ#, Zhang Z, Liu DD, Manolios EN, Chen C, Yan X, Zuo W, Chen NH*. J Neurosci Methods. 2018 Sep 1;307:60-69.

29.  IMM-H004, a Novel Coumarin Derivative Compound, Inhibits H2O2-Induced Neurotoxicity via Antioxidant and Antiapoptosis in PC12 Cells. Song XY#, Hu JF, Wu DH, Ji HJ, Chen NH*. J Stroke Cerebrovasc Dis. 2018 Dec;27(12):3396-3403.

30.  Corticosterone impairs gap junctions in the prefrontal cortical and hippocampal astrocytes via different mechanisms. Xia CY#, Wang ZZ, Zhang Zhao, Chen J, Wang YY, Lou YX, Gao Y, Luo P, Ren Q, Du GH, Chen NH*. Neuropharmacology. 2018 Mar 15;131:20-30.

31.  Progress in Pharmacological Research of chemokine like factor 1 (CKLF1). Liu DD#, Song XY, Yang PF, Ai QD, Wang YY, Feng XY, He Xin, Chen NH*. Cytokine. 2018 Feb;102:41-50.

32.  Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Zhang QS#, Heng Y, Mou Z, Huang JY, Yuan YH*, Chen NH*. Acta Pharmacol Sin. 2017 Oct;38(10):1317-1328.

33.  Ginsenoside Rg1-induced antidepressant effects involve the protection of astrocyte gap junctions within the prefrontal cortex. Jin C#, Wang ZZ, Zhou H, Lou YX, Chen J, Zuo W, Tian MT, Wang ZQ, Du GH, Kawahata I, Yamakuni T, Zhang Y, Chen NH*, Zhang DS*. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:183-191.

34.  Possible target-related proteins of stress-resistant rats suggested by label-free protemic analysis. Chen J#, Wang ZZ, Zhang S, Ai QD, Chu SF, Chen NH*. RSC Advances 2017; 7: 40957-40964.

35.  Upregulating the Expression of Survivin-HBXIP Complex Contributes to the Protective Role of IMM-H004 in Transient Global Cerebral Ischemia/Reperfusion. Chu SF#, Zhang Z#, Zhang W, Zhang MJ, Gao Y, Han N, Zuo W, Huang JY, Chen NH*. Mol Neurobiol. 2017 Jan;54(1):524-540.

36.  Pathological α-synuclein exacerbates the progression of Parkinson’s disease through microglial activation. Zhang QS#, Heng Y, Yuan YH*, Chen NH*. Toxicol Lett. 2017 Jan 4;265:30-37.

37.  IMM-H004, a coumarin derivative, attenuated brain ischemia/reperfusion injuries and subsequent inflammation in spontaneously hypertensive rats through inhibition of VCAM-1. Yang PF#, Song XY, Zeng T, Ai QD, Liu DD, Zuo W, Zhang S, Xia CY, He X, Chen NH*. RSC Advances 2017; 7: 27480–27495.

38.  Ginsenoside Rg1 alleviates corticosterone-induced dysfunction of gap junctions in astrocytes. Xia CY#, Chu SF, Zhang S, Gao Y, Ren Q, Lou YX, Luo P, Tian MT, Wang ZQ, Du GH, Tomioka Y, Yamakuni T, Zhang Y, Wang ZZ*, Chen NH*. J Ethnopharmacol. 2017 Aug 17;208:207-213.

39.  A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the a-Synuclein–Related Inflammatory Response. Zhang QS#, Heng Y, Chen Y, Luo P, Wen L, Zhang Z, Yuan YH*, Chen NH*. J Pharmacol Exp Ther. 2017 Nov;363(2):284-292.

40.  Antidepressive effects of ginsenoside Rg1 via regulation of HPA and HPG axis. Mou Z#, Huang Q#, Chu SF, Zhang MJ, Hu JF, Chen NH*, Zhang JT*. Biomed Pharmacother. 2017 Aug;92:962-971. 

 

专利

1.     一种香豆素衍生物代谢产物的制备及其在防治脑缺血和阿尔茨海默病中的应用、专利申请人:陈乃宏;李燕;戴均贵;宋修云;盛莉;乐田;楚世峰;张梓倩;解可波;谭圳、授权公告日:2021112

2.     一类来源连翘的化合物、其制法及在防治帕金森病的应用、专利申请人:陈乃宏;张培成;宋修云;张凡;张挽青;杨桠楠;冯子明;姜建双、授权公告日:201911

3.     一类黄烷化合物在防治神经退行性疾病中的应用、专利申请人:张培成;陈乃宏;贠菊平;宋修云;杨桠楠;冯子明;姜建双、授权公告日:2020218

4.     一种连翘活性部位的制备及其在防治帕金森病中的应用、专利申请人:张培成;陈乃宏;张凡;宋修云;杨桠楠;张帅;冯子明;姜建双、授权公告日:2019423

5.     香豆素衍生物的制备及其在防治脑部重大疾病中的应用、专利申请人:刘刚;陈乃宏;孙明娜;胡金凤;宋修云、授权公告日:20171222

6.     天麻中具有神经细胞保护活性的多聚苄类衍生物、专利申请人:石建功;陈乃宏;王亚男;苑玉和;林生;吴苗苗;郭庆兰;朱承根、授权公告日:2017426

7.     黄皮咔唑生物碱及其制备方法和其药物组合物与用途、专利申请人:张东明;陈乃宏;柳航;宁娜、授权公告日:201632

8.     拮抗CKLF1/CCR4相互作用的3-哌嗪基香豆素衍生物、专利申请人:刘刚;陈乃宏;王冬梅;李刚、授权公告日:20141217

 

 

内部链接
相关链接